CTX-320

N/A

Report date: 2025/06/16 10:39:54

Base Information

Drug NameCTX-320
Drug Alias NameCTX-320CTX320
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionApolipoprotein(a) inhibitors
TargetsApolipoprotein(a)
Therapy Area/IndicationsMetabolic DiseasesAtherosclerosisAortic Valve Stenosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsMetabolic DiseasesAtherosclerosisAortic Valve Stenosis
Inactive IndicationsCardiovascular DiseasesMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A